Gland Pharma Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Q4FY26 Audited Financial results".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma reported record Q4 FY26 results with consolidated revenue of ₹17,428 million, up 22% YoY, and adjusted PAT of ₹3,667 million, surging 97% YoY. The company achieved an adjusted EBITDA margin of 30% in Q4, up from 24% in Q4 FY25. For the full year FY26, revenue grew 14.5% to ₹64,307 million with PAT up 50% to ₹10,455 million. The CDMO (contract manufacturing) segment contributed 46% of revenues and grew 36% YoY in Q4. The Board recommended a final dividend of ₹20 per share. The company launched 31 products in the US during FY26 and filed 24 ANDAs.
Strong Q4 results with near-doubling of PAT and margin expansion signal operational efficiency improvements and robust CDMO momentum. The dividend announcement and 22% revenue growth are positive signals for shareholders, though investors should monitor the relatively low EBITDA performance at Cenexi subsidiary (1% margin in Q4).